R. Silvariño, Leticia Peluffo, Eliana Cabrera, Sofía San Román, C. Baccino, Óscar Noboa
{"title":"常染色体显性肾多囊卵巢综合征:谁受益于tolvaptan治疗?最先进的","authors":"R. Silvariño, Leticia Peluffo, Eliana Cabrera, Sofía San Román, C. Baccino, Óscar Noboa","doi":"10.29193/rmu.38.3.11","DOIUrl":null,"url":null,"abstract":"Autosomal dominant polycystic kidney disease is the most common hereditary kidney disease. It is charac - terized by the progressive appearance of renal cysts that usually lead to extreme chronic kidney disease in adulthood. The approval of the use of tolvaptán (V2 va-sopressin receptor antagonist) has meant a significant change in the treatment of this disease. In recent years, evidence has proved the benefits of initiating treatment with tolvaptán in patients with a rapidly evolving disease. A descriptive review of the main clinical studies published in 2012-2022 period is carried out and a use-ful scheme is suggested to select","PeriodicalId":51931,"journal":{"name":"Revista Medica del Uruguay","volume":"58 1","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2022-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Poliquistosis renal autosómica dominante: ¿quiénes se benefician del tratamiento con tolvaptán? Estado del arte\",\"authors\":\"R. Silvariño, Leticia Peluffo, Eliana Cabrera, Sofía San Román, C. Baccino, Óscar Noboa\",\"doi\":\"10.29193/rmu.38.3.11\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Autosomal dominant polycystic kidney disease is the most common hereditary kidney disease. It is charac - terized by the progressive appearance of renal cysts that usually lead to extreme chronic kidney disease in adulthood. The approval of the use of tolvaptán (V2 va-sopressin receptor antagonist) has meant a significant change in the treatment of this disease. In recent years, evidence has proved the benefits of initiating treatment with tolvaptán in patients with a rapidly evolving disease. A descriptive review of the main clinical studies published in 2012-2022 period is carried out and a use-ful scheme is suggested to select\",\"PeriodicalId\":51931,\"journal\":{\"name\":\"Revista Medica del Uruguay\",\"volume\":\"58 1\",\"pages\":\"\"},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2022-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Medica del Uruguay\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29193/rmu.38.3.11\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Medica del Uruguay","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29193/rmu.38.3.11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Poliquistosis renal autosómica dominante: ¿quiénes se benefician del tratamiento con tolvaptán? Estado del arte
Autosomal dominant polycystic kidney disease is the most common hereditary kidney disease. It is charac - terized by the progressive appearance of renal cysts that usually lead to extreme chronic kidney disease in adulthood. The approval of the use of tolvaptán (V2 va-sopressin receptor antagonist) has meant a significant change in the treatment of this disease. In recent years, evidence has proved the benefits of initiating treatment with tolvaptán in patients with a rapidly evolving disease. A descriptive review of the main clinical studies published in 2012-2022 period is carried out and a use-ful scheme is suggested to select
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
